{"name":"Incyte Corporation","slug":"incyte","ticker":"INCY","exchange":"NASDAQ","domain":"incyte.com","description":"Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI for the treatment of myelofibrosis (MF), polycythemia vera, and steroid-refractory acute graft-versus-host disease; ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; MONJUVI/ MINJUVI for the treatment of diffuse large B-cell lymphoma and Follicular Lymphoma; NIKTIMVO for the treatment of chronic graft-versus-host disease. It also provides INCA033989 for the treatment of essential thrombocythemia and MF;  INCA035784 for the treatment of anti-mutant calreticulin and myeloproliferative neoplasms (MPNs); INCB160058 for the treatment of MPNs; PEMAZYRE, a selective fibroblast growth factor receptor kinase inhibitor for the treatment of unresectable biliary tract cancer, metastatic cholangiocarcinoma, and myeloid/lymp","hq":"Wilmington, DE","founded":0,"employees":"2844","ceo":"Hervé Hoppenot","sector":"Specialty Pharma","stockPrice":94.67,"stockChange":0.98,"stockChangePercent":1.05,"marketCap":"$18.8B","metrics":{"revenue":3394635000,"revenueGrowth":27.8,"grossMargin":52.9,"rdSpend":2050152000,"netIncome":1286650000,"cash":3097817000,"dividendYield":0,"peRatio":14.8,"fiscalYear":"FY2022"},"revenueBreakdown":[{"name":"Pemazyre","genericName":"PEMIGATINIB","slug":"pemigatinib","revenue":200000000,"yoyGrowth":0,"percentOfTotal":100}],"timeline":[{"date":"2020-01-01","label":"Pemazyre first approved","drug":"Pemazyre","drugSlug":"pemigatinib","type":"approval","sentiment":"positive"},{"date":"2023-01-01","label":"Zynyz first approved","drug":"Zynyz","drugSlug":"retifanlimab","type":"approval","sentiment":"positive"},{"date":"2024-01-01","label":"Niktimvo first approved","drug":"Niktimvo","drugSlug":"axatilimab","type":"approval","sentiment":"positive"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-09-01","label":"Niktimvo PHASE2 readout","drug":"Niktimvo","drugSlug":"axatilimab","type":"phase3_readout","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2030-06-01","label":"Jakafi patent cliff ($1.4B at risk)","drug":"Jakafi","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":200000000,"percentOfTotal":100,"drugCount":3,"colorKey":"oncology","drugs":[{"name":"Pemazyre","genericName":"PEMIGATINIB","slug":"pemigatinib","indication":"Biliary tract cancer","status":"marketed","revenue":200000000},{"name":"ZYNYZ","genericName":"RETIFANLIMAB-DLWR","slug":"retifanlimab-dlwr","indication":"Merkel cell carcinoma","status":"marketed"},{"name":"Zynyz","genericName":"RETIFANLIMAB","slug":"retifanlimab","indication":"Merkel cell carcinoma","status":"marketed"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"Niktimvo","genericName":"AXATILIMAB","slug":"axatilimab","indication":"chronic graft-versus-host disease (cGVHD)","status":"marketed"},{"name":"R-CHOP","genericName":"R-CHOP","slug":"r-chop","indication":"Other","status":"marketed"}]}],"pipeline":[{"name":"Pemazyre","genericName":"PEMIGATINIB","slug":"pemigatinib","phase":"marketed","mechanism":"Pemazyre blocks the activity of the FGFR1 protein, which is involved in the growth and spread of cancer cells.","indications":["Biliary tract cancer","FGFR1 fusion genepositive myeloid/lymphoid neoplasm","Malignant neoplasm of common bile duct (& [carcinoma])"],"catalyst":""},{"name":"Niktimvo","genericName":"AXATILIMAB","slug":"axatilimab","phase":"marketed","mechanism":"Niktimvo blocks the Colony Stimulating Factor-1 Receptor to reduce inflammation and prevent damage to healthy tissues.","indications":["chronic graft-versus-host disease (cGVHD)"],"catalyst":""},{"name":"R-CHOP","genericName":"R-CHOP","slug":"r-chop","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ZYNYZ","genericName":"RETIFANLIMAB-DLWR","slug":"retifanlimab-dlwr","phase":"marketed","mechanism":"Programmed cell death protein 1","indications":["Merkel cell carcinoma"],"catalyst":""},{"name":"Zynyz","genericName":"RETIFANLIMAB","slug":"retifanlimab","phase":"marketed","mechanism":"Zynyz works by blocking the PD-1 receptor on immune cells, allowing them to recognize and attack cancer cells.","indications":["Merkel cell carcinoma"],"catalyst":""}],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"Incyte Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Incyte reported fourth quarter and full year 2023 financial results, with net product sales of $1.4 billion for the year.","drugName":"","sentiment":"neutral"},{"date":"2023-12-14","type":"deal","headline":"Incyte and Novartis Announce Collaboration to Develop and Commercialize Pemazyre in Japan","summary":"Incyte and Novartis announced a collaboration to develop and commercialize Pemazyre in Japan.","drugName":"","sentiment":"positive"},{"date":"2023-11-15","type":"regulatory","headline":"FDA Approves Pemazyre for Treatment of Cholangiocarcinoma","summary":"The FDA approved Pemazyre for the treatment of cholangiocarcinoma.","drugName":"","sentiment":"positive"}],"realNews":[{"date":"2026-03-30","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-03-26","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxQSFBZTlNES2pteV8zVFJFZi1hLUNpZzdCcnJKaVhqQmR5b2x4cWZaYUJGNFIwaW5hWmVUenZxTThPbmFSM3M4QUZZT0ZBVWNYRkJNaXhra2YyeXk3LXg2Z21iTkRqV2tXRWZLNHlYUVFtZEVDeENaVWtUTWNGRlpSaTFKcWtDUnhaN3d2YzN2cHlZMzBkUEZfV0E2OA?oc=5","date":"2026-03-09","type":"regulatory","source":"Finviz","summary":"INCY Wins EC Approval for Label Expansion of Oncology Drug Zynyz - Finviz","headline":"INCY Wins EC Approval for Label Expansion of Oncology Drug Zynyz","sentiment":"positive"},{"date":"2026-03-06","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxPbUhrMEt2MGJDaElKdEwtSElVVUVKdFF4RU9VMGU3VkRlR1hPazlfaXh2aDJoMUJSRTRXV2Y5aHoxLUhSY1FsTk5IRER6Uk91OV9fbFRBQ3JJY0Rwdy1USTdtd0U5ZkdOWUlGdUx2THlvNWdSd0VTY3lyS2h1TXY3MnBDekhRSWpsZ3VXV0dzbGlRQzI0d3o0XzBn?oc=5","date":"2026-03-02","type":"pipeline","source":"Finviz","summary":"LLY Wins CHMP Nod for Olumiant's Expanded Use in Alopecia Areata - Finviz","headline":"LLY Wins CHMP Nod for Olumiant's Expanded Use in Alopecia Areata","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxNb0pEUU9RR2t1LTV4MzRpb2thQnZrblZYUjE5Z09IcFNsN1BuTEFhcmwyajF4WVNLOGlrSHZMN3RHUXJ0a2UzRzNacEVNbERJMDczV21ncFhzTC1uc2JwU0FTQUxQWkR4emk2R1djbDNMWDJzMGtoTTF2SlRGeWxqSXctbGVHSG4wWHV0cmI1S2poaVY2QkZ4QmtIc2xUZVU?oc=5","date":"2026-02-18","type":"regulatory","source":"Seeking Alpha","summary":"Incyte Remains Undervalued As Opzelura And Niktimvo Scale (NASDAQ:INCY) - Seeking Alpha","headline":"Incyte Remains Undervalued As Opzelura And Niktimvo Scale (NASDAQ:INCY)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1AFBVV95cUxPSm50ZHJEU2lBRzBxZmI3SWpVZTJLNWJXbkd6WXNJNkhDUmVFc21oc1FrUDVlSV9fcnpJNEQ2WjdpYVdQeWtFX2hfMTNfTUdpR3NBaXFpeFpkVkxaTGZfU0xENlRTT1lKTGJJckc0UE42UWt1RDdfNXV4WnVfeUh6aV9MUzF6OExCSjB3TnRpN0NSSU43V3VqNFl3VGJjZEY4UEVEX1dHQkk2eDNMNXg3elVkbHFuV2Y3dEc5MWVMREt5OHJIemxYRnBhanRGQktVOHZheA?oc=5","date":"2026-02-13","type":"earnings","source":"Reuters","summary":"Incyte's weak Opzelura 2026 revenue forecast heightens Jakafi patent concerns - Reuters","headline":"Incyte's weak Opzelura 2026 revenue forecast heightens Jakafi patent concerns","sentiment":"neutral"},{"date":"2026-02-10","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-02-10","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxPR2w2U1E2NjZFNmgzNkZDS0dSOF9aaVpCM3d4SGhxZDRHdWtneDBldlpjSG1RTnVpcWhHa0FCMjFzMWNOcDM1cmd3VUptTG5hRnFpYjVhdWFyeFN2S0pKOFpucXlSTC1heEFNam9lOGNvYllSZFl4X1JhdlFVRGJBcDV1LTZXUFd3QjRkQ0F6UjFBQQ?oc=5","date":"2026-01-22","type":"deal","source":"Seeking Alpha","summary":"What Investors Should Know Before Buying Incyte Stock (NASDAQ:INCY) - Seeking Alpha","headline":"What Investors Should Know Before Buying Incyte Stock (NASDAQ:INCY)","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-11-17","type":"pipeline","source":"simplywall.st","summary":"Trade Alert: Advisor to CEO & Director Of Incyte Herve Hoppenot Has Sold Stock - simplywall.st","headline":"Trade Alert: Advisor to CEO & Director Of Incyte Herve Hoppenot Has Sold Stock","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMifkFVX3lxTFBiekhlOUpBd29yR2dsVVFsR1o4Z256a2hPUmZ3ejQxRVZRUUpsb0k2WGtSOWo4c2YwYjJUenZzQ3RqVFdNRkJNRFdObE9WbDFPVERTNVdjd2tpZHp3LU52SjhrcjA3clpsRUEyR0pJd3VqUzROVDJFY1dLMy1PUQ?oc=5","date":"2025-11-03","type":"pipeline","source":"StocksToTrade","summary":"Incyte’s Impressive Surge: Analyze the Gains - StocksToTrade","headline":"Incyte’s Impressive Surge: Analyze the Gains","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigwFBVV95cUxPc01LTXR4VmM3Y0t6WjNtdUtoUlpEVEdWRTdMaE5QNzNvWnE5ajFmbFNNSTlpZ21GT0c0aFhfYXRCYm5aR2xtWHZva0VKeUstdkF5RW8wUkk4aUoyekYzSlFpX0FHam5wUTdHQU4yNmZuMTRIYXFJcmxhWjRtd3V2TzZEbw?oc=5","date":"2025-10-01","type":"pipeline","source":"Yahoo Finance","summary":"Incyte (INCY) Price Target Lifted on CALR Antibody Program Optimism - Yahoo Finance","headline":"Incyte (INCY) Price Target Lifted on CALR Antibody Program Optimism","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiigFBVV95cUxPbUg1cmVfUW9pa3M0TGJ4Rkt4cm9TVUpIcE90cmN4djNHdG02dWktdnNwTldYODZ1V25GQVREN3pQc0x6UHV4RlREa1ROS1pUVWxGNlBTcV9ydkdrby1LakNtSzB1YW8tVzdHeWZuaGxaeVhfNlpyczJocTJmWElyR3pQdV9MVnFrLVE?oc=5","date":"2025-09-26","type":"trial","source":"Yahoo Finance","summary":"Incyte (INCY) Advances Clinical Trials for Povorcitinib Across Multiple Conditions - Yahoo Finance","headline":"Incyte (INCY) Advances Clinical Trials for Povorcitinib Across Multiple Conditions","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-08-14","type":"pipeline","source":"simplywall.st","summary":"Incyte Corporation's (NASDAQ:INCY) Price Is Right But Growth Is Lacking After Shares Rocket 26% - simplywall.st","headline":"Incyte Corporation's (NASDAQ:INCY) Price Is Right But Growth Is Lacking After Shares Rocket 26%","sentiment":"neutral"}],"patents":[{"drugName":"Jakafi","drugSlug":"ruxolitinib","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":1400000000}],"drugCount":5,"phaseCounts":{"marketed":5},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Gilead Sciences","Bristol Myers Squibb","Merck & Co."],"therapeuticFocus":["Oncology","Inflammation"],"financials":{"source":"sec_edgar","revenue":3394635000,"revenuePeriod":"2022-12-31","revenueHistory":[{"value":3394635000,"period":"2022-12-31"},{"value":2986267000,"period":"2021-12-31"},{"value":2666702000,"period":"2020-12-31"},{"value":2158759000,"period":"2019-12-31"},{"value":1881883000,"period":"2018-12-31"},{"value":1536216000,"period":"2017-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":2050152000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":1286650000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":3097817000,"cashHistory":[],"totalAssets":6957973000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":94.67,"previousClose":93.69,"fiftyTwoWeekHigh":112.29,"fiftyTwoWeekLow":53.56,"fiftyTwoWeekRange":"53.56 - 112.29","fiftyDayAverage":97.98,"twoHundredDayAverage":90.85,"beta":0.86,"enterpriseValue":15119983616,"forwardPE":10.9,"priceToBook":3.64,"priceToSales":3.66,"enterpriseToRevenue":2.94,"enterpriseToEbitda":10.5,"pegRatio":0.35,"ebitda":1439769984,"ebitdaMargin":28,"freeCashflow":609552000,"operatingCashflow":1413497984,"totalDebt":54920000,"debtToEquity":1.1,"currentRatio":3.32,"returnOnAssets":13.6,"returnOnEquity":29.9,"analystRating":"2.3 - Buy","recommendationKey":"buy","numberOfAnalysts":22,"targetMeanPrice":107.27,"targetHighPrice":135,"targetLowPrice":71,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":1.9,"institutionHeldPercent":105.3,"sharesOutstanding":199014486,"floatShares":166624878,"sharesShort":11044905,"shortRatio":7.07,"shortPercentOfFloat":5.5,"epsTrailing":6.41,"epsForward":8.65,"revenuePerShare":26.34,"bookValue":26.04,"officers":[{"age":62,"name":"Dr. Pablo J. Cagnoni M.D., Ph.D.","title":"President and Global Head of Research & Development"},{"age":58,"name":"Dr. Steven H. Stein M.D.","title":"Executive VP, Head of Late-stage Development & Chief Medical Officer"},{"age":57,"name":"Mr. William J. Meury","title":"CEO & Director"},{"age":47,"name":"Mr. Thomas  Tray","title":"Principal Financial Officer, VP of Finance & Chief Accounting Officer"},{"age":61,"name":"Mr. Michael James Morrissey","title":"Executive VP & Head of Global Technical Operations"},{"age":null,"name":"Ms. Alexis  Smith","title":"Vice President & Head of Investor Relations"},{"age":null,"name":"Mr. Richard A. Hoffman J.D., M.B.A.","title":"Executive VP & General Counsel"},{"age":74,"name":"Ms. Pamela M. Murphy","title":"Vice President of Investor Relations & Corporate Communications"}],"industry":"Biotechnology","irWebsite":"http://investor.incyte.com/phoenix.zhtml?c=69764&p=irol-irhome","website":"https://www.incyte.com","phone":"302 498 6700"}}